166402-16-0

Basic information

• Product Name: 6-Quinoxalinamine, 3-chloro-
• Synonyms: 6-Quinoxalinamine, 3-chloro-;3-Chloroquinoxalin-6-amine
• CAS NO: 166402-16-0
• Molecular Formula: C₈H₆ClN₃
• Molecular Weight: 179.61
• Mol File: 166402-16-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 339.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.445±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.66±0.10(Predicted)
• CAS DataBase Reference: 6-Quinoxalinamine, 3-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Quinoxalinamine, 3-chloro-(166402-16-0)
• EPA Substance Registry System: 6-Quinoxalinamine, 3-chloro-(166402-16-0)

Safety Data

• Hazardous Substances Data: 166402-16-0(Hazardous Substances Data)

Upstream product

• 1196-57-2 2-hydroxyquinoxaline 
• 89898-96-4 2-Hydroxy-7-nitroquinoxaline 
• 1084-76-0 DNP-Gly 
• 98555-00-1 7-aminoquinoxalin-2(1H)-one 
• 89898-96-4 7-nitroquinoxaline-2(1H)-one 
• 55686-94-7 2-Chloro-7-nitroquinoxaline 
• 251474-50-7 7-amino-3,4-dihydro-1H-quinoxalin-2-one 

Relevant articles and documents

1, 4, 8-Triazaphenanthrene Derivatives For The Treatment Of Neurodegenerative Disorders

The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said compounds, and to the

New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models

Parkinson's disease (PD) is a neurodegenerative disorder of aging characterized by motor symptoms that result from the loss of midbrain dopamine neurons and the disruption of dopamine-mediated neurotransmission. There is currently no curative treatment for this disorder. To discover druggable neuroprotective compounds for dopamine neurons, we have designed and synthesized a second-generation of quinoxaline-derived molecules based on structure-activity relationship studies, which led previously to the discovery of our first neuroprotective brain penetrant hit compound MPAQ (5c). Neuroprotection assessment in PD cellular models of our newly synthesized quinoxaline-derived compounds has led to the selection of a better hit compound, PAQ (4c). Extensive in vitro characterization of 4c showed that its neuroprotective action is partially attributable to the activation of reticulum endoplasmic ryanodine receptor channels. Most interestingly, 4c was able to attenuate neurodegeneration in a mouse model of PD, making this compound an interesting drug candidate for the treatment of this disorder.